David Parker is a General Partner at Ampersand Capital Partners, a private equity firm with $800 million of capital under management. His experience includes investments in various healthcare sectors, including clinical diagnostics products, laboratory services, life science research products, medical devices, pharmaceutical outsourcing services and specialty pharmaceuticals. He has served on the Board of Directors of ACLARA Biosciences, Bako Pathology Services, Blue Sky Bioservices, IBT Laboratories, Modified Polymer Components (MPC), NOVEX (Life Technologies), Ortho Organizers, Signature Genomic Laboratories and Stereotaxis. He has also served as Chief Financial Officer at several Ampersand portfolio companies.

Prior to joining Ampersand Capital Partners in 1994, Parker was a management consultant at Bain & Company and Mercer Management Consulting, where he provided strategy and operations consulting services to clients in the healthcare, transportation, consumer products and telecommunications sectors. Parker began his career as a corporate lending officer at First National Bank of Boston (now part of Bank of America).

Parker earned his B.A. in Government from Dartmouth College and an M.B.A. with a concentration in Finance from the Wharton School.